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 INTRODUCTION   
          Blood transfusion is a life saving modality. The transfusion of 
blood and blood products is much safer than ever before but still a long 
way from achieving universal access to safe blood transfusion.1 
            A Transfusion Transmitted Infection (TTI) is any potential 
pathogen that can be transmitted in donated blood through a transfusion 
to a recipient. The magnitude of the problem of transfusion transmitted 
diseases varies from country to country depending on disease 
prevalence. Various measures are taken in a country to make blood 
transfusion therapy safe for the respective population.  
          There is a long list of viruses, parasites and bacteria and recently 
prion diseases, which can be transmitted through blood transfusion. 
Majority of the problems are due to the prevalence of asymptomatic 
carriers in the society as well as blood donations during window period 
of infections. Viral infections assume a great importance in transfusion 
associated mortality and morbidity in patients. Important transfusion 
transmitted viruses are HIV, HBV, HCV, HTLV, Parvo virus B-19 and 
cytomegalovirus.2 
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          Over the years, there has been a substantial decline in the 
incidence of transfusion-transmitted infections due to improvement in 
donor screening, blood product testing and viral inactivation of blood 
products, particularly in developed nations. However, in developing 
nations, blood safety continues to be a major problem due to the high 
prevalence of infectious markers among blood donors compounded with 
the problem of limited resources that preclude the use of sophisticated, 
sensitive but expensive technologies for screening of blood products.3  
          The last two decades have also witnessed surfacing of new and re-
emerging infections. Hence, despite stringent donor eligibility criteria, 
improved donor screening and introduction of sophisticated technology, 
transfusion-transmitted infection continues as a challenge for transfusion 
experts. 
          Cytomegalovirus (CMV), a member of the human herpes family 
of viruses, transmissible through blood transfusions, is an important 
cause of concern world wide.4  
          CMV is a ubiquitous agent and seropositivity rates in the 
population are 60 to 100%.5 CMV is one of the most significant 
pathogens infecting immuno suppressed individuals. Like most other 
herpes viruses, they remain latent in the host after primary infection and 
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persist for life long in the organism.  Nevertheless, these viruses can be 
reactivated in immuno suppressed individuals leading to various critical 
outcomes.6 
          In immunocompromised recipients, transmission rates of up to 
50% have been reported from blood components.7  
          Therefore, the most effective way to minimize the risk of CMV 
transmission in high risk recipients would be to administer CMV free 
blood products. The immuno suppressed population for whom CMV 
free blood products are requested is increasing due to advances in 
medical care. This means that considerable stress is placed on blood 
banks to maintain adequate inventory of these products.8 
          In view of the increasing demand for CMV free blood products, 
this study was performed to determine the seroprevalence of CMV 
antibodies among voluntary blood donors. 
          An estimate of the seroprevalence of CMV among voluntary 
blood donors may be of help to decide whether screening for CMV 
would eliminate transmission of infection to high risk groups. Such 
studies have been very few in India. The current study was undertaken 
in an attempt to address this aspect. Such information may be invaluable 
to health planners and policy makers. 
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AIM AND OBJECTIVES 
AIM 
 The aim of the study is to find out the seroprevalence of Human 
Cytomegalovirus among voluntary blood donors in Chennai. 
OBJECTIVES 
• To detect IgM and IgG anti-CMV antibodies among healthy 
blood donors. 
• To confirm CMV seronegative samples for CMV DNA by 
PCR analysis. 
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REVIEW OF LITERATURE 
Blood transfusion is an essential element of a health care system. 
Millions of lives are saved each year through blood transfusions. 
Inadequacies in blood safety and supply, contribute significantly to the 
burden of disease and loss of life.9  
Blood transfusion has revolutionized modern medicine. By 
maintaining blood volume, replacing deficient blood components and 
improving oxygen transportation, transfusion has expanded the 
boundaries of modern medicine, allowing many crucial surgical 
procedures, organ transplants, and cancer therapies to be performed.  
            Blood transfusions, however, are not risk-free. Despite significant 
improvements in safety measures, blood transfusions are still associated 
with a residual risk of infection by various pathogens, many of which 
are serious and life threatening. The safety assessment of the blood 
supply, the quality of screening procedures, and the risk of transfusion-
transmitted infectious diseases in any country can be estimated by 
review and analysis of the records of blood donors, screening 
procedures, and the prevalence of serological markers of infectious 
diseases.10  
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          A report of an infection suspected to be due to transfusion was 
classified as a transfusion-transmitted infection if the following criteria 
were met at the end of the investigation.11 
a) The recipient had evidence of infection post-transfusion, and there 
was no evidence of infection prior to transfusion and no evidence of 
an alternative source of infection 
b) Atleast one component received by the infected recipient was 
donated by a donor who had evidence of the same transmissible 
infection, or 
c) Atleast one component received by the infected recipient was shown 
to contain the agent of infection.  
          The goal of any transfusion service is to provide blood 
components that are safe for the transfusion and pose minimal risk of 
transfusion transmitted infections.  
Transfusion transmissible agents have certain characteristics.12 
1.  Persistence in blood for relatively long period of time 
2.  Giving rise to carrier or latent state 
3.  Causation of disease with long incubation period 
4.  Ability to cause symptomatic infections 
5.  Stability in cold stored blood 
 7
           To achieve maximum safety at an acceptable cost, it requires a 
multilayered risk reduction strategy involving safe blood donors, safe 
blood components and safe transfusion practices.13  
 
 
 
 
 
 
 
 
 
Multilayered risk reduction strategy13 
 
 
Donor eligibility 
Careful donor selection lowers risk of dispensing blood products obtained during window period 
Screening tests 
Bacterial detection methods for platelets may detect most contaminated units 
NAT testing combined with serology for viral infection decreases the residual risk
Processing, quality control 
Improved donor Skin disinfection and  diversion of first 30ml of blood reduces contamination 
Audits and quality control assessments of the procedures during product 
 processing ensures highest safety standards 
Storage, pathogen inactivation 
Optimize storage temperature and time Pathogen inactivation 
procedures that do not compromise  product integrity 
Indication for transfusion 
Assess the need for each individual transfusion
Traceability, 
Hemovigilance Systems 
Reporting of adverse events 
National and international networks 
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          Blood transfusion is a unique technology that blends science with 
altruism. Though its collection, processing and use are technical, its 
availability depends entirely on the extraordinary generosity of the 
blood donor who donates this most precious of gifts – the gift of life. 
Safe transfusion not only requires the application of science and 
technology to blood processing and testing, but also social mobilization 
to promote voluntary blood donation by sufficient numbers of people 
who are healthy and are at low risk of infections that can be transmitted 
to the recipients of their blood.14 
            Voluntary Blood Donors form the cornerstone of a safe and 
adequate supply of blood and blood products. Voluntary blood donor 
refers to unpaid, non-remunerated blood donors. He is an altruistic 
donor who gives blood freely and willingly without receiving money or 
any other form of payment.15              
           Over the past decade, efforts have been made to quantify the risks 
of transfusion-transmitted infectious diseases accurately. Although, 
numerous analyses on risk of human immunodeficiency virus (HIV) 
infection have been made, there are fewer reliable estimates of infection 
rates for the other major transmissible agents by transfusion. Accurate 
estimations on risk of transfusion transmitted viral infections are needed, 
in order to monitor the safety of the blood supply and evaluate the cost 
effectiveness of new screening tests. 
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           The most direct way to evaluate the transfusion associated risk is 
to study the rate of infection prospectively in transfusion recipients. The 
current very low risk of transfusion transmitted infectious diseases 
makes such studies impractical because an exceedingly large number of 
recipients are required for the risk to be measured accurately. 
Alternatively, the infection rate in donated blood samples can be 
determined by testing with extremely sensitive assays.10 
           In India, donor blood is screened for Human Immunodeficiency 
Virus I & II (anti-HIV), Hepatitis B virus (HbsAg), Hepatitis C Virus 
(anti-HCV), syphilis and malaria.16 
HUMAN HERPES VIRUS 
          The Herpesviridae is a family of approximately 100 viruses with 
common structural features. Of the herpes viruses, only eight are known 
to infect human beings, which are termed as Human Herpes Viruses.  
Members of the Human Herpes Virus (HHV) family are categorized into 
three subfamilies based on biologic properties including cell tropism, 
genome structure and sequences of conserved open reading frames.17  
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Members of the Herpesviridae Family18 
SUBFAMILY 
HHV 
DESIGNATION
COMMON NAME 
Alphaherpesvirinae HHV-1 Herpes simplex-1 
HHV-2 Herpes simplex-2 
HHV-3 Varicella Zoster Virus 
Betaherpesvirinae HHV-5 Cytomegalovirus 
HHV-6A,-6B             - 
HHV-7             - 
Gammaherpesvirinae HHV-4 Epstein-Barr Virus 
HHV-8 Kaposi’s sarcoma 
associated Herpes virus 
 
CYTOMEGALOVIRUS 
           Cytomegalovirus (from the Greek cyto-, "cell", and -megalo-, 
"large") is a human herpes virus belonging to the Betaherpesvirinae 
subfamily. It is designated as Human Herpesvirus 5 (HHV-5). CMV 
was the first identified beta herpes virus and remains the prototype of 
this group.19 
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STRUCTURE 
                       
 
 
 
 
 
The CMV virus contains a linear double-stranded DNA genome 
of approximately 230 kbp in length, the largest of the herpes virus. The 
genome is surrounded by an icosadeltahedral nucleocapsid. The 100 nm 
diameter capsid, composed of 162 capsomeres, is encompassed by a 
dense tegument or matrix and an outer trilaminar lipid envelope that 
contains proteins of both viral & host cell origins.20 
           The genome is divided into unique long (UL) and unique short 
(US) segments, each flanked by a pair of inverted repeat regions.21  The 
unique long and unique short segments can each independently invert 
with respect to one another, yielding four different genomic isomers. 
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After infection, the termini of the linear genome are joined to produce a 
circular replicative form.  Mature virions range from 150-200 nm in 
diameter and contain approximately 30 viral proteins distributed in the 
capsid, tegument and envelope.22 
BIOLOGY OF INFECTION       
 CMV can infect a range of cell types, including those of 
endocrinal, epithelial, mesenchymal, hematopoietic and neuronal 
lineages; frequently causing characteristic cellular enlargement-
cytomegalia (Fig 1).23 Infections appear to involve three sequential 
steps:  
1.  Viral attachment to the target cell. 
2.  Fusion of the viral and cellular membranes.  
3. Penetration of the viral capsid into the cell.  
           After these steps, active infection occurs if the target cell is 
permissive for the complete sequence of viral gene expression, viral 
genome replication and production of progeny virions.  Finally mature 
virions are transported through the Golgi apparatus and are released 
from infected cells by exocytosis eventually resulting in host cell 
destruction.24 
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 CMV may also assume a latent state when it infects target cells 
that are not permissive for viral replication.  Latency, the presence of 
viral DNA in an infected cell in the absence of active viral replication, 
may persist indefinitely because the host cell is not destroyed by the 
virus.  The latent CMV genome retains the capacity to reactivate viral 
gene expression, produce infectious virions, and enter lytic growth at a 
later time.25  
           CMV infection alters the expression, accumulation and activity of 
the cellular tumour suppressor proteins, cyclins and cyclin associated 
kinases. These alterations in the cell cycle machinery act to promote 
progression toward the G1/S transition but prevent cellular DNA 
synthesis and cell division, resulting in cell cycle arrest and cellular 
aneuploidy.  It has been hypothesized that in the arrested state, cellular 
DNA synthesis would be blocked but the cellular milieu would contain 
abundant nucleotides and other metabolic processors that could support 
viral replication.26, 27 
 Slobedman et al demonstrated that latency can be established in 
hematopoietic cells, primarily those of the Granulocyte-Monocyte 
lineage.28 Monocytes are a prominent site of CMV latency and 
monocyte derived macrophages can support active CMV replication.29 
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CMV TRANSMISSION 
 During CMV infection, active viral replication results in shedding 
of infectious virions into plasma and body fluids including saliva, tears, 
breast milk, urine, stool and semen.   
          Community acquired CMV infection is usually the result of close 
contact with a person shedding CMV.   
          The yearly CMV seroconversion rate in health care workers has 
been estimated at 0.6 to 3.3%, similar to rates of 2% to 6.3% reported in 
middle class women during and between pregnancies.30  
           In contrast, rates as high as 13% per year have been observed in 
adolescents.31 The CMV seroconversion rate in blood donors is 
estimated at approximately 1% per year.32, 33   
          Most individuals contracting community acquired CMV infection 
are immunocompetent and the infection is often asymptomatic.  
However, a mild self-limited infectious mononucleosis syndrome can 
occur, with symptoms that include fever, malaise, hepatosplenomegaly 
and a rash.  CMV can be isolated from body secretions during the 
symptomatic phase.  The infected individual mounts both a humoral and 
cell mediated immune response and viral symptoms rapidly resolve, 
leading to a complete recovery.  However, despite effective control of 
CMV infection by the competent host immune system, the virus is not 
completely eliminated but instead becomes latent. 
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Presentations of Acute Cytomegalovirus Infection in a Normal 
Person34 
Common Less common Rare 
Asymptomatic (most 
common) 
Exudative 
pharyngitis 
Icteric hepatitis 
Mononucleosis syndrome Splenomegaly 
Guillain-Barré 
syndrome 
Fever 
Cervical 
adenopathy 
Encephalitis 
Malaise Nonspecific rash Myocarditis 
Sore throat Anemia Pneumonitis 
Headache   
Increased levels on liver 
function tests 
  
Lymphocytosis   
Antibiotic rash   
 
          CMV can be transmitted by blood transfusion, transplacental 
route or by transplantation of hematopoietic stem cells and solid organs 
from infected donors. When the recipients are immunocompromised, 
CMV transmission through these mechanisms can produce serious 
clinical consequences.  
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PATHOGENESIS  
 The most important target cells of CMV infection are peripheral 
blood leukocytes and their progenitors.  These cell types can either 
harbor latent CMV or allow active viral replication and thus are well 
suited to mediate transfusion transmitted CMV infection. 
 CMV infection of bone marrow hematopoietic progenitor cells 
(CD34+ cells) likely occurs during primary infection. Most evidence 
suggests that these cells restrict viral replication but support viral 
latency, although some studies have shown low levels of CMV 
replication.35 Because of their capacity for self renewal, latently infected 
hematopoietic progenitor cells represent a potential long term reservoir 
of latent virus.  Latently infected marrow progenitor cells are a likely 
vector for transmission of CMV infection by hematopoietic stem cell 
transplantation. 
 Myeloid lineage committed CD33+ progenitor cells also appear to 
be latently infected. As CD33+ progenitors continue to differentiate, 
they enter the peripheral blood. Monocytes appear to retain latent virus, 
but as they differentiate into macrophages, CMV replication with 
production of progeny virus has been observed. These findings support a 
model for latency in which early hematopoietic progenitor cells are 
latently infected during primary infection and thereafter serve as viral 
reservoirs. 
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          Tolpin et al provided the first biochemical and molecular evidence 
for transfusion transmitted CMV infection.  They reported that cells of 
the monocyte lineage have been hypothesized to mediate transfusion 
transmitted CMV, but the prevalence of latently infected monocytes in 
the peripheral blood appears to be low.36  
          Kenneth et al indicated that WBCs of the monocyte lineage are 
the most likely to carry latent CMV in seropositive donors.35  
Circulating latently infected monocytes must be able to support viral 
reactivation from latency to mediate transfusion transmitted CMV.  
These cells became permissive for CMV reactivation and viral 
replication after exposure to T-Cell conditioned medium and 
hydrocortisone or the combination of IFN-2, TNF and IL-4 
respectively.37 
           It has been estimated that 0.01% to 0.12% of Peripheral blood 
mononuclear cells (PBMNC) from healthy seropositive blood donors 
contain CMV DNA with a range of 2 to 13 viral genomes per infected 
cell.28  Approximately 5% of PBMNC are monocytes, so latently 
infected monocytes may comprise only 1 to 25 of every million 
peripheral blood WBCs.  This low number of latently infected 
leukocytes in transfused blood components may contribute to the 
variable incidence of transfusion transmitted CMV observed clinically.  
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           Plasma free virus appears to be less stable than intracellular virus 
and the presence of free virus in plasma is usually transient.38 
Zanghellini et al reported that in recently infected adolescents, 25-40% 
had plasma viremia, which was rarely identified more than four months 
after seroconversion.31  
TRANSFUSION TRANSMITTED CMV INFECTIONS 
 By the mid 1960s, a number of investigators had described an 
illness with clinical similarities to infectious mononucleosis occurring in 
patients who were exposed to blood products during cardiopulmonary 
bypass for open heart surgery.39 Patients typically presented with fever, 
splenomegaly and atypical lymphocytosis within 3-8 weeks of surgery 
but had a negative heterophile antibody test and did not experience 
exudative pharyngitis or lymphadenopathy.  
          Klemola et al and kaariainen et al subsequently demonstrated an 
increase in the titer of complement fixing anti-CMV antibodies 
concurrent with the illness, suggesting that the etiology was CMV 
infection acquired from transfused blood products.40, 41 
 Transfusion can lead to active CMV infection in the recipient by 
three mechanisms.   
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I) The term Transfusion Transmitted CMV (TT-CMV) is used to 
describe a primary   CMV infection occurring in a seronegative 
recipient transfused with an infectious blood component.  
II) Reactivated CMV infection can occur when a seropositive 
transfusion recipient experiences reactivation of their latent CMV 
infection after blood transfusion.  
III) CMV super infection (second strain infection) occurs when a 
seropositive recipient contracts a new strain of CMV from an 
infectious blood component.  
          Transfusion transmitted CMV results in a primary infection 
against which the recipient has no pre existing immunologic memory.  
In contrast, CMV reactivation and super infection occurs in a patient 
having previous CMV infection. 
          The diagnosis of both reactivation and super infection is based on 
a four fold or greater rise in the titer of anti CMV antibodies and/or 
renewed viral shedding in secretions of seropositive transfusion 
recipients.42 The incidence of CMV reactivation is independent of donor 
serostatus.43 Although reactivation and super infection can be 
distinguished from one another by restriction endonuclease genotyping 
of CMV strains, this analysis has no significant clinical implications.36 
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 These three mechanisms of transfusion associated CMV infection 
appear to occur with similar frequencies. A review by Adler et al, about 
transfused CMV seropositive patients, calculated a 26% cumulative 
incidence of CMV reactivation or super infection compared to a 31% 
incidence of transfusion transmitted CMV (primary CMV infection) in 
seronegative recipients.42  
           It should be noted that although most cases of suspected 
transfusion transmitted CMV result from the transfused component, a 
minority of cases may result from community-acquired CMV 
infection.44 
BLOOD COMPONENTS ASSOCIATED IN TT-CMV 
           The primary vector for TT-CMV is the CMV infected leukocyte. 
All cellular components are implicated in transmitting CMV infection. 
TT-CMV has not been observed in patients receiving blood components 
that are free of WBCs. The absence of CMV transmission through 
transfusion of FFP may be due to the scarcity of plasma free virus in 
healthy seropositive donors as well as neutralization of virus by anti 
CMV antibodies.45   
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 Meyers et al reported that there is a high frequency of TT-CMV 
following transfusion of seropositive blood enriched for WBCs and 
demonstrated TT-CMV after granulocyte transfusion (57.1%, p<0.001) 
from seropositive donors transfused to seronegative recipients.46 
 Ping-Ing Lee et al suggested that fresh blood from seropositive 
donors was more infectious than stored blood (87% versus 17%, 
p=0.01%).47 However, not all studies have demonstrated an effect of 
product storage interval on the incidence of TT-CMV. 
Blood Components implicated in TT-CMV  
Blood 
Component TT-CMV risk Methods to prevent TT-CMV 
Red cells Yes Screening, Filtration, Frozen-
deglycerolized 
Platelets Yes Screening, Filtration 
Granulocytes Yes Screening 
FFP No Not applicable 
Cryoprecipitate No Not applicable 
Clotting factors No Not applicable 
 
 The risk of TT-CMV also varies with different groups of 
transfusion recipients. Preiksaitis had suggested that the following 
factors may also predispose to TT-CMV: - sequential transfusion over a 
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long period of time as compared to large transfusion volumes given at 
one time, the use of HLA-matched donors, repetitive transfusions from 
the same donor and the degree of immunosuppression and cytokine 
expression profile in the host. This makes it very difficult to assign a 
specific risk per CMV seropositive unit transfused.32, 33 
PATIENTS AT RISK FOR TT-CMV32, 33 
Category A: (Populations in whom the use of CMV-“safe” cellular 
blood products have been proven to reduce the incidence and morbidity 
of CMV infection using controlled trials) 
● Low birth weight infants born to seronegative mothers 
● Seronegative recipients of seronegative donor bone marrow 
(allogeneic)  
● Seronegative recipients of autologous bone marrow transplants 
Category B: (Populations at high risk of significant morbidity as the 
result of transfusion-acquired CMV infection, but the incidence of 
transfusion-acquired CMV infection in these populations has not been 
clearly documented or the benefit of using CMV-“safe” cellular blood 
products has not been proven) 
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● Seronegative pregnant women requiring antepartum transfusion 
or intrauterine blood transfusions and seropositive women 
requiring intrauterine blood transfusions in the second trimester 
● Low birth weight infants born to seronegative or seropositive 
mothers or other seronegative immunosuppressed patients 
requiring granulocyte transfusions 
● Seronegative recipients of seronegative donor lungs and livers 
and possibly other organs 
● Seronegative HIV-infected and AIDS patients and children born 
to HIV-infected mothers 
Category C: (Populations who may be at higher risk of transfusion-
acquired CMV infection or its morbidity, but in whom the incidence or 
morbidity or transfusion acquired CMV infection is low or poorly 
documented) 
● Low birth weight infants born to seropositive mothers 
● Infants with birth weights > 1,500 g born to seronegative mothers 
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● Neonates receiving ECMO (extracorporeal membrane 
oxygenation) and other neonates requiring extensive transfusion 
support (i.e. exchange transfusion, cardiovascular surgery) 
● Seronegative recipients of seronegative donor kidneys and hearts 
● Seronegative patients with malignant disease receiving 
chemotherapy 
● Seronegative patients with hematological or genetic disorders 
requiring repetitive transfusions in whom bone marrow 
transplantation may be a future therapeutic option 
● Seronegative patients experiencing major trauma or splenectomy 
Category D: (Populations in which the incidence and morbidity 
associated with transfusion acquired CMV infection is low, the use of 
CMV-“safe” cellular blood products is not indicated) 
● Infants with birth weights > 1,500 g born to seropositive mothers 
● Other seronegative immunocompetent patients 
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The most well established patient groups at risk for TT-CMV 
include48, 49 
1. Premature Low Birth Weight infants (<1250-1500g) born to 
seronegative mothers 
2. Seronegative recipients of seronegative allogenic or autologous Bone 
Marrow Transplant (BMT) 
3. Seronegative recipients of seronegative solid organ transplants  
          Immuno compromised patients have higher rates of CMV 
infection and CMV disease compared to immunocompetent 
individuals.46   
          Wilhelm et al showed that less than 1.2% of immunocompetent 
patients experienced transfusion transmitted CMV. But, the incidence of 
community acquired CMV infection  is relatively greater (1.7% per 
patient year) than transfusion transmitted CMV in immunocompetent 
population.50 Although transfusion transmitted CMV produces primary 
CMV infection in the immunocompetent transfusion recipient, it is of no 
more clinical significance than community acquired CMV infection. 
Thus at present there are no compelling reasons to provide non-immuno 
suppressed seronegative transfusion recipients with special components 
for the purposes of preventing transfusion transmitted CMV.  
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          However, TT-CMV can be an important cause of morbidity and 
mortality in immuno compromised patients.  Most studies suggest that 
13-38% of these patients will contract CMV from transfusion of 
unscreened and unfiltered cellular blood components.47, 51, 52 
          The first manifestations are often a viral syndrome characterized 
by flu like illness, including fever, chills, malaise, leucopenia and 
thrombocytopenia.  It can progress to CMV hepatitis, retinitis, 
interstitial pneumonitis, encephalitis and gastro enteritis.   Progression to 
disease is more likely in patients with elevated viral loads. 
          Transplancental transmission of CMV to a developing fetus is an 
important viral cause of birth defects.53 Fetal infection occurs in 40 to 
50% of cases in which a seronegative mother contracts a primary CMV 
infection during pregnancy. CMV disease occurs in 5-15% of the 
infected infants, presenting with intra uterine growth retardation, 
deafness, mental retardation, blindness and thrombocytopenic 
bleeding.54 
          However, when mothers are seropositive before pregnancy, 
maternal antiviral immunity can limit congenital CMV infection and 
disease but they can also be at risk for lethal CMV infection, despite the 
transfer of humoral immunity especially in low birth weight infants.    
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          Stagno et al stated that the rate of vertical transmission was 
approximately 1% among seropositive mothers.54 
 Ping-Ing Lee et al reported that seronegative children transfused 
with unscreened blood products had a 36% (14 of 39) incidence of TT-
CMV.47   
          The morbidity in neonates weighing less than 1250-1500g with 
transfusion acquired CMV infection born to seronegative mothers 
ranged from 40% to 100% while the mortality ranged from 20% to 57% 
which is mainly due to their immature immune systems.55  
          Preiksaitis et al documented that primary CMV infection during 
pregnancy carries high risks of congenital fetal infection.  As the 
primary maternal infection resulting from TT-CMV can in turn lead to 
fetal infection, it is prudent to provide CMV safe blood components to 
pregnant women who are seronegative.56 
 Marrow transplant recipients are at significant risk of morbidity 
and mortality from CMV infection.  Up to one third of those patients 
who contract CMV infection can develop CMV pneumonitis, a 
frequently fatal complication.46   
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          In seronegative recipients of seronegative marrow or autologous 
transplants, transfusion is the primary mechanism for CMV infection 
whereas in seropositive marrow recipients, CMV infection is usually 
due to viral reactivation.52, 57 
          The development of GVHD affects the incidence of CMV 
infection and disease in BMT patients. Miller et al reported that CMV 
infection occurred in 42% of allogenic bone marrow transplant patients 
who developed GVHD and in only 20% of those who did not develop 
GVHD.57 The incidence of CMV interstitial pneumonitis in seronegative 
recipients of allogenic BMT was significantly greater than the 
autologous BMT particularly if the allogenic recipients developed 
GVHD.                           
          Solid organ transplant recipients are also susceptible to CMV 
infection and disease.  In contrast to Bone marrow transplantation, the 
most important source of CMV infection is the donor organ, with TT-
CMV being less significant.58, 59  
          In seronegative recipients of seronegative organs, transfusion of 
unscreened blood products has been associated with an incidence of 
CMV ranging from     15% to 20%.55  
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          Among organ transplant recipients, those receiving heart, heart-
lung, liver and pancreas transplants usually require numerous 
transfusions and thus have an increased risk (up to 33%) of TT CMV.  
Hillyer et al showed that even in heavily transfused organ transplant 
recipients, the use of seronegative blood products could effectively 
prevent transfusion transmitted CMV.60 
          Previously, CMV was not considered to be oncogenic but recent 
studies show that they too play a role in carcinogenesis.  Bongers et al 
reported that CMV promotes development of intestinal dysplasia and 
cancer in transgenic mice and suggest that CMV infection may facilitate 
development of intestinal neoplasia in humans. Centre for molecular 
medicine, Sweden revealed the frequent presence of CMV genome in 
certain malignant tumours. Whether CMV is causative or simply 
represents an epiphenomenon of malignant tumors requires further 
elucidation.61 If this has been proved, considerable stress will be placed 
on blood banks to provide CMV free components. 
LABORATORY DIAGNOSIS 
          Accurate detection of CMV infection enables the identification of 
transfusion recipients at risk for CMV infection, as well as blood donors 
whose components are potentially infectious.   
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          CMV may be routinely detected in infected individuals either by 
the direct identification of infectious virus or viral nucleic acid proteins 
or indirectly by the serological measurement of the CMV specific 
antibody response.                
          The standard approach for identifying a previously infected 
individual is through detection of anti CMV antibodies.  Serologic 
assays have been developed in multiple configurations, including 
indirect hemagglutination, complement fixation, solid phase 
fluorescence immuno assay, enzyme immuno assay (EIA), latex or 
particle agglutination and solid phase red cell adherence, although the 
first three of these techniques are no longer frequently used.20  
          Current transfusion practice is to use EIA designed to detect CMV 
specific antibody.  These techniques are used qualitatively and have 
several distinct advantages for transfusion services as they are sensitive 
(93%), specific (95%), rapid and can be automated for high sample 
throughput.60  
          EIA systems that detect both CMV specific IgG & IgM are to be 
preferred as the IgM component may improve identification of those 
donors with acute, but sub-clinical CMV infection.   
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          The incidence of new CMV infection is estimated to be 1% per 
annum in adults.  However, anti-CMV antibodies may not be detected 
by serology until 6 to 8 weeks after primary infection and serology 
cannot accurately identify or quantitate the extent of active CMV 
infection (Fig 2). 
          Poor antibody responders to CMV may also be unreactive leading 
to additional false negative EIA test results.  Therefore apparently CMV 
seronegative blood components may contain and transmit infectious 
virus. This accounts for occasional TT CMV infections seen despite the 
use of seronegative products. 
          An alternative to serological testing is direct detection of the virus 
or its component nucleic acid / proteins.  Viral culture is relatively 
insensitive but unequivocally determines whether or not infectious virus 
is present and therefore provides an excellent inferred measure of blood 
product infectivity.  However, prolonged assay times (>48 hours) make 
this approach impractical for the routine screening of blood donations.    
          Antigenemia assays, frequently based on detection of the CMV 
tegument phosphoprotein pp65, are used to monitor clinical infection in 
patients. This method is used for early quantitative detection of CMV 
infections, allowing the institution of preemptive (presymtomatic) 
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antiviral therapies. Owing to their relative insensitivity at low viral 
loads, they are of limited value in determining the CMV status of 
latently infected blood donors. 
          The recent introduction of quantitative PCR assays for CMV may 
provide a more rapid, sensitive and specific predictor of patient at risk 
for CMV disease.62  Advantages of the PCR method included reduced 
turn around time, smaller sample requirements, simplified specimen 
processing, improved stability of specimens. PCR can be useful in 
detecting CMV DNA either from the plasma or WBC during window 
period (Fig 2). 
PREVENTION OF TT-CMV 
 The incidence of TT-CMV as well as that of other untoward 
effects of transfusion can be reduced by limiting transfusion to 
appropriate, clinically indicated circumstance.  However, when 
transfusions are necessary, the most common approaches to decrease the 
risk of TT-CMV are the use of blood components that are considered 
CMV safe.   
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I) SERONEGATIVE BLOOD COMPONENTS  
           The exclusive use of seronegative units in immunocompromised 
adult seronegative recipients of allogenic seronegative bone marrow 
transplants decreased the incidence of CMV and severity of resulting 
CMV disease as compared to the use of unscreened blood products.  
           However, the use of seronegative units was only beneficial in 
seronegative recipients of seronegative donor marrow.  Seronegative 
recipients of seropositive marrow transplants had a 46% incidence of 
CMV infection when transfused with unscreened blood which was not 
significantly different from the 32% incidence when these patients 
received seronegative blood products.52  
           The potential activity of screening donors for CMV antibody to 
prevent    TT-CMV infections and disease was highlighted by a series of 
important studies over the past three decades.  
           Luthardt & Colleagues in 1971 showed that 0 of 20 seronegative 
exchange transfused infants receiving seronegative donor blood 
acquired CMV infection, whereas 8 of 15 (53%) seronegative infants 
who were exchange transfused with CMV seropositive blood became 
infected.63  
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           Yeager & associates published that 0 to 90 seronegative infants 
receiving seronegative blood became infected with CMV; in contrast, 10 
of 74 (13.5%) seronegative infants receiving seropositive blood were 
infected, 5 of whom manifested serious or fatal CMV infections.51 
          Despite exclusive use of seronegative units for transfusion, up to 
4% of susceptible recipients have acquired CMV.64 Several explanations 
for the failure of antibody screening to eliminate TT-CMV infections are 
possible, including the presence of strain variants undetected by current 
antibody assays, insensitive antibody assays, waning antibody in 
formerly seropositive donors (Seroreversion) and transmission during 
the antibody negative window phase of infection.  Alternatively some of 
these infections may not be transfusion related, but instead result from 
non parental spread that occurs in the general population. 
          Alternatively, some donors may have been in the 6 to 8 week 
window phase following primary CMV infection during which anti-
CMV antibodies cannot be detected reliably.31  During this period there 
are high peripheral blood viral loads, suggesting that transfusion from 
these seronegative donors may be infectious. 
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          Although most CMV antibody tests are based on the broadly 
reactive strain AD169, it is theoretically possible that currently used 
tests might not detect some infections caused by variant strains.  There 
is, however, no solid evidence to substantiate this contention.  Antigenic 
variation among CMV strains was documented by cross-neutralization 
studies shortly after the virus was first isolated, but the amount of 
variation was not sufficient to warrant designating different serotypes.  
Thus strain variation is unlikely to account for the occurrence of break 
through infections in high risk patients given seronegative blood 
components.  CMV is thought to establish a latent infection with 
periodic reactivations, providing an immune stimulus that ensures life 
long antibody positivity in the vast majority of infected persons.62 
II) FILTERED BLOOD COMPONENTS 
 The difficulties in maintaining a sufficient inventory of CMV 
seronegative blood components, due to its high prevalence, motivated 
efforts to identify alternative strategies to provide CMV safe 
components for susceptible patients.  Removal of WBCs from 
components was an attractive approach to mitigate TT-CMV. Current 
generation of leukofilters have excellent leukocyte removal efficiency 
(99.99% -3 to 4 log 10  reduction) as compared to the previous generation 
filters (90-96%).65 
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          The primary mechanism of leukocyte removal is the charge-based 
adhesion of negatively charged leukocytes to the filter material by 
Vander Waals and electrostatic forces. This adhesion is an active 
process and has the advantage of larger pore size, by which a subsequent 
higher flow rate is possible in the filter. The surface charge of the filters 
can be modified by coating the filter material with methacrylate 
polymers, to create a stronger positive charge and hence increase the 
efficiency of the filter.66  
          Alternatively, platelets and red cells can be prepared from donors 
by apheresis procedure, resulting in components with 105 to 106 residual 
leukocytes.  This level of leukoreduction has been shown to 
significantly reduce the incidence of TT-CMV.67, 68 
          Prestorage leukoreduction may reduce the risk of  CMV 
transmission by blood products not only by reducing the number of 
latently infected cells infused but also by reducing the probability of 
initiating CMV reactivation events driven by cytokine release from 
donor leukocytes in a blood component before infusion. 
          The American Association of Blood Banks (AABB) has 
suggested that residual leukocyte levels less than 5 x 106 make a blood 
product CMV-“safe”. In its theoretical limit, the infusion of a single 
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latently infected donor leukocyte may be sufficient to infect a 
susceptible recipient.  However, in practical terms, because the 
pathogenesis of transfusion-acquired CMV infection involves a complex 
interaction between donor and recipient factors, leukoreduction to less 
than 5 x 106   leukocytes in a blood product may make the sequence of 
events required to reactivate CMV from latency in almost all transfusion 
recipients so improbable, that the blood product could be considered 
CMV-“safe.”  
          Although the AABB guidelines state that seronegative and 
leukoreduced units are equivalent for prevention of TT-CMV, other 
panels disagree.  A Canadian consensus reached a conclusion, when the 
majority of the panel agreed that, seronegative blood components should 
continue to be provided to at risk patients despite implementation of 
universal leukoreduction in Canada.69 
Wu Y et al reported that transfusion transmitted CMV may still 
occur in the era of universal leukoreduction.70 
         Lipson et al stated that Plasma viremia, if present, would not be 
diminished by leukoreduction and could explain CMV transmission 
events following use of leukoreduced components.71 
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          In order to directly compare the incidence of TT-CMV with 
seronegative and filtered components, Bowden & Colleagues 
prospectively randomized seronegative bone marrow transplant 
recipients to receive transfusions of either seronegative blood units or 
unscreened filtered blood products.  The incidence of CMV infection 
was comparable in both groups (1.3% in the seronegative arm Vs 2.4% 
in the leukoreduction arm).  However, the incidence of CMV disease 
and CMV related mortality was slightly higher in the leukoreduced arm 
of the study (0% Vs 2.4%) p=0.03.64 
 Nicholas et al reported the longest clinical study that assessed the 
efficacy of serological screening versus WBC reduction.  This 
investigator concluded that CMV seronegative components is superior 
to WBC reduced components in preventing TT-CMV infection and the 
abandonment of CMV seronegative inventories in an era of universal 
WBC reduction is probably immature.72 
         The University Health system Consortium (UHC) consensus 
recommends that leukoreduced components may be considered 
equivalent to seronegative components but they may not be applicable to 
all immunosuppressed individuals. A decision to order leukoreduced 
components should be based on patient’s immune status, underlying co- 
morbidities and overall physical condition.73  
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         Smith et al reported that though both seronegative and 
leukoreduced products were considered equivalent by many institutions, 
the reported practices for specific patient populations did not match this 
view of equivalence, with many patient populations preferentially 
receiving CMV seronegative components.  Fetal and neonatal 
populations were more likely than other patient populations to receive 
CMV seronegative products to reduce the risk of TT-CMV.74 
         Canadian consensus concluded that CMV serologic testing might 
add to the benefit of leukoreduction in those patients at highest risk of 
developing CMV disease and there is no evidence that abandoning 
serologic testing does not lead to a slight, but clinically important 
increase in CMV transmission.72 
         The Council of Europe has endorsed the use of leucodepleted 
cellular blood components as a safe substitute for CMV seronegative 
blood components where the latter are unavailable.20 
         Malte et al reported that donors who were seropositive for atleast 1 
year   did not show the presence of CMV DNA. Hence, blood products 
from these donors can be leukoreduced and transfused for 
immunocompromised patients when seronegative blood is not 
available.75 
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         When assessing the overall cost-benefit of leucodepletion Vs 
serological screening, the additional benefits of leucodepletion should 
also be taken into account.  Leucodepletion, as an alternative to CMV 
testing, has been shown to prevent primary allosensitization in > 97% of 
transfusion recipients and FNHTR.  By contrast, the sole benefit of 
CMV antibody testing is prevention of CMV transmission.  
Disadvantages of serological testing include selective screening for 
certain patients, associated clerical errors and insufficient inventory of 
CMV seronegative products, particularly in emergencies.20                   
III) NUCLEIC ACID AMPLIFICATION TESTING (NAT) 
SCREENED COMPONENTS 
          NAT is currently used to screen for HIV and HCV in blood 
donations suggesting that NAT for CMV DNA may be a useful adjunct 
to serology and filtration in preventing TT-CMV.  
          However, CMV NAT poses problems not encountered with HIV 
AND HCV screening. Because most seropositive donors who are 
immunocompetent are remotely infected (>6 months), they are likely to 
have peripheral blood viral loads near or below the limits of detection of 
even sensitive NAT assays.  Assays sufficiently sensitive to detect these 
low viral loads may be subject to problems including non-specific 
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amplification of background DNA. This high DNA content may 
adversely affect the signal to noise ratio of NAT assays.  Thus it is not 
surprising that previous applications of NAT to detect CMV DNA in 
healthy blood donors have produced conflicting results.18  
          Marc Mendelson et al have identified CMV DNA in both 
seropositive and seronegative donors.76 Andreas et al identified CMV 
DNA in 5 of 27 of healthy blood donors.77 In contrast, Bitsch et al and 
Smith et al have been unable to identify CMV by PCR in peripheral 
blood from seropositive or seronegative donors.78, 79 They concluded 
that CMV genome copy number in healthy individuals is beyond the 
detection limit of PCR technology. David Hudnell et al reported CMV 
DNA in only 1% of the healthy donors.80 
          To address the inconsistent results of earlier studies, a multicentre 
trial was performed by Roback JD et al to directly compare the 
performance characteristics of CMV PCR assays when applied to 
healthy blood donors.  They found only 0.5% of samples from healthy 
CMV seropositive blood donors to have reproducibly detectable CMV 
DNA loads when using extremely sensitive PCR assays.  Based on these 
results, the current CMV PCR assays do not appear to improve upon the 
ability of serological screening to prevent TT-CMV.81  
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          Dumont & Coworkers have published a provocative study 
suggesting that CMV DNA in blood may vary seasonally with higher 
levels of viremia coinciding with increased tree pollen concentration.  If 
the hypothesis is confirmed, it is possible that higher rates of plasma 
CMV DNA might be detected during periods when immunologic 
stimulation of donors is enhanced because of allergen exposure.82 
          Boom et al observed that the CMV DNA present in the plasma 
and serum of renal transplant recipients with primary CMV infection 
was highly fragmented and therefore unlikely to represent incubating 
infectious virus.83  If this finding can be validated by others, it would 
allay concerns expressed by Drew et al that plasma viremia may be 
source of residual CMV transmission when WBC reduced or 
seronegative cellular blood components are used.38  It would also 
explain the clinical observation that plasma and plasma products do not 
appear to transmit CMV. 
           It should be noted that minimal viral load required for TT-CMV 
has not been determined and it must be assumed at present that any 
CMV-seropositive or CMV DNA positive unit is potentially infectious. 
 With standard serologic assays, both uninfected donors and those 
in the window phase of a CMV infection test as seronegative.  Some 
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window phase donors have high plasma & WBC-associated viral loads 
and thus although seronegative, their blood may be infectious on 
transfusion.84 NAT may serve as a useful adjunct to serology and 
filtration in those who are in window period. 
IV) FROZEN DEGLYCEROLISED COMPONENTS 
 The exclusive use of frozen-deglycerolized red cells markedly 
reduces the incidence of TT-CMV. Robert et al stated that only 0.8% of 
the seronegative bone marrow patients got seroconverted after receiving 
frozen deglycerolized RBCs. However, given the labor intensive nature 
of preparing frozen–deglycerolized red cells and its cost, this approach 
is rarely used.85   
V) WASHED COMPONENTS 
          It is unclear whether washing of components can adequately 
decrease the incidence of TT-CMV. Grundy et al86 reported that 
transfusion of washed cells resulted in an 11% incidence of CMV in 
seronegative neonates while Gail Demmeler et al87 reported 1.3% 
incidence. The variable rates may be explained by the variations in 
washing protocols. Still, most authorities do not equate washed RBCs 
with seronegative components for the prevention of TT-CMV. 
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VI) IMMUNOGLOBULIN PREPARATION AND ANTIVIRAL 
DRUGS 
          A meta-analysis of prophylactic IVIg in BMT patients confirmed 
that passive CMV antibodies could significantly reduce fatal CMV 
infection, CMV pneumonitis and total CMV mortality. However, the 
efficacy of IVIg in preventing TT-CMV is more difficult to assess. 
There was no significant effect of IVIg on CMV infection and disease, 
when seronegative patients were transfused with seronegative blood. 
Further, IVIg was ineffective in preventing TT-CMV in seronegative 
patients who received seropositive granulocyte transfusion.  
          Ganciclovir can provide effective prophylaxis against CMV 
disease. However, it can cause marrow suppression predisposing to 
opportunistic infections. Broers et al reported severe neutropenia in 33% 
of treated patients.88 These patients experienced increased mortality due 
to other infections despite control of CMV infection. 
          When compared to the proven efficacy of seronegative or filtered 
units in preventing TT-CMV, the use of IVIg and antiviral agents would 
be more expensive and possibly not as effective, and thus these 
interventions cannot be recommended for abrogation of TT-CMV. 
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VII) GAMMA IRRADIATION AND PATHOGEN 
INACTIVATION  
Gamma-Irradiation of cellular blood components to minimum 
doses of 2500 cGy (25 Gy) to the mid-plane of the container and 1500 
cGy to all other parts is used to prevent TA-GVHD. This prevents 
thymidine incorporation by lymphocytes after mitogenic stimuli. A 500-
cGy dose may suffice to prevent the physiologically relevant 
proliferation in mixed lymphocyte culture. Doses <5000 cGy do not 
affect RBC, platelet or granulocyte function and survival adversely. But 
to prevent CMV transmission, Gamma-Irradiation cannot be used 
because the dose needed to inactivate the virus can damage blood cells.89 
As opposed to current approaches such as the use of seronegative 
and filtered components, the application of pathogen inactivation 
technology to cellular blood components carries the potential for 
completely preventing TT-CMV as well as eliminating the transmission 
of other infectious agents. In the presence of ultra violet light, psoralen 
based compounds such as 8- methoxypsoralen can inactivate a spectrum 
of pathogens, including viruses and bacteria in blood components. It has 
effectively prevented transfusion transmitted CMV in a murine 
transfusion model and clinical trials are warranted in humans.90 
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MATERIALS AND METHODS 
STUDY METHOD 
 This prospective study was conducted over one year period from  
2009-2010 in the Department of Transfusion Medicine, The Tamilnadu 
Dr.MGR Medical University, Guindy, Chennai. A total of 180 voluntary 
blood donors were selected.   The study was approved by the ethical 
committee of the Tamil Nadu Dr. MGR Medical University, Chennai. 
The donors were classified as higher, middle and lower socioeconomic 
status based on Kuppusamy classification. 
SAMPLE COLLECTION 
 Five ml of blood from each donor was collected from the 
collection bag into a sterile capped tube. It was then centrifuged and 
plasma was separated and stored as 2 aliquots at -80°C till further use. 
INCLUSION CRITERIA 
• Donors who are eligible for blood donation as per the NACO 
guidelines. 
• Donors reactive for any of the existing mandatory test, as per 
the NACO guidelines, are also included. 
• Donors who are willing to participate in the study by giving 
written consent. 
 
 47
EXCLUSION CRITERIA 
          All voluntary donors not willing to give consent to participate in 
the study 
STATISTICAL ANALYSIS 
 Statistical analysis was done with “Chi-square Test” using 
statistical software packages (Microsoft Excel, SPSS15). Groups were 
assumed to differ significantly when the probability (p value) was less 
than 0.001 (1% Level) or 0.05 (5% level). 
METHOD OF SCREENING 
The samples that were frozen earlier were thawed and used. Sera 
were tested for IgG and IgM CMV by the enzyme-linked 
immunosorbent assay (ELISA) test. The CMV-specific antibodies were 
studied by the commercial Diagnostika Nord CMV IgG ELISA Kit (Fig 
3) and CALBIOTECH CMV IgM ELISA Kit (Fig 4). This is based 
upon the use of micro titration wells coated with purified antigen. All 
steps were done according to the manufacturer's instructions. Reading 
was taken at 450nm wavelength using a microplate reader (Fig 5, 6). 
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CMV DNA DETECTION 
 The detection of CMV DNA in the CMV seronegative samples 
was done by real time PCR using Roche light cycler (Fig 7). The DNA 
was extracted from the plasma by Shanghai ZJ Bio-Tech CMV Real 
time PCR Kit.  
THE PROTOCOL FOR THE DNA PURIFICATION FROM 
PLASMA  
Procedure 
         DNA extraction buffer supplied in the kit is thawed thoroughly 
and spin down briefly in the centrifuge before use.  
1) Pipette 50μl serum or plasma to a 0.5ml tube, add 50μl DNA 
extraction buffer, and close the tube then vortex for 10 seconds. 
Spin down briefly in a table centrifuge. 
2)  Incubate the tube for 10 minutes at 100°C. 
3)  Centrifuge the tube at 13000rpm for 10 minutes. The supernatant 
contains the DNA extracted and can be used for the template of 
the PCR. 
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PROCEDURE OF DNA AMPLIFICATION 
PCR Primers 
Forward Primer : 5' GAG GAC AAC GAA ATC CTG TTG 
GGC A 3’    
Reverse Primer  : 5' GTC GAC GGT GGA GAT ACT GCT 
GAG G 3’ 
Probe : 5’ GGA CTA CCT CTT CAA ACG CAT 
GAT TGA C 3’  
(3’fluorescein label)  
Real time cycles condition 
 Reaction mixture was prepared as follows: 
Fast start DNA master hybridization probe - 2µl 
Forward primer                                             - 2µl            
Reverse primer                                              - 2µl 
Probe                                                             - 2µl 
Magnesium chloride                                     - 3.2µl 
Water                                                            - 3.8µl  
          15µl of the reaction mix is dispensed straight into the Light cycler 
capillary. 5µl of the DNA extract, positive/ negative control is added. 
Capillaries are capped and spinned at 1000rpm for 10seconds to deposit 
the reaction mix at the base of the reaction capillary. It is transferred to 
the Roche Light cycler. 
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DNA is amplified as follows: 
          Denaturation done at 95o C for 30 sec. Amplification at 60o C for 
45 seconds and extension at 72o C for 30 seconds 
 Finally melting curve analysis was done. This is a step built into 
the software of real time cycles. 
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RESULTS 
TABLE 1 
 Gender Distribution of the Study Group 
Sex Number of donors Percent % 
Male  137 76.1 
Female 43 23.9 
Total 180 100.0 
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Fig 6 
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TABLE 2 
Age Distribution of the Study Group 
Age group 
In years 
Number of 
Donors 
Percent % 
18-20 60 33.3 
21-25 62 34.4 
26-30 34 18.9 
31-35 14 7.8 
36-40 8 4.4 
> 40 2 1.1 
TOTAL 180 100.0 
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TABLE 3  
Distributions On The Basis Of Occupation 
 
Occupation Number Of Donors Percentage% 
Professionals             65             36.1 
Students             74             41.1 
Clerical job             24             13.3 
Coolie             17              9.4 
Total             180            100.0 
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 TABLE 4  
Distribution of Blood Group 
Blood Group Number of Donors Percent % 
A Positive 39 21.66 
A Negative 4 2.2 
B Positive 55 30.55 
B Negative 3 1.7 
O Positive 64 35.6 
O Negative 4 2.2 
AB Positive 11 6.1 
AB negative 0 0.0 
Total 180 100.0 
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TABLE 5  
Distribution On The Basis Of Socioeconomic Status 
Socioeconomic status Number of donors Percentage % 
High               23           12.78 
Middle              131           72.77 
Low               26            14.44 
Total              180           100.0 
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TABLE 6  
Transfusion Transmitted Infection Status 
TTI Status Number of donors Percentage % 
Reactive                 1(HbsAg)             0.56 
Non-Reactive              179            99.44 
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TABLE 7  
Anti-CMV Antibody screening by ELISA 
Anti-CMV antibody         Positive     Negative 
         IgG              167          13 
         IgM                0         180 
                                                                                                 P=0.000 
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TABLE 8  
PCR results in IgG seronegative donors 
IgG Anti-CMV Negative                13 
PCR positive                 0 
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TABLE 9  
Age Distribution of IgG seropositives 
Age group 
In years 
IgG seropositive 
donors (Total donors) 
Percent % 
18-20 56(60) 93.33% 
 21-25 58(62) 93.54% 
26-30 30(34) 88.23% 
31-35 13(14) 92.85% 
36-40 8(8) 100% 
> 40 2(2) 100% 
TOTAL 167(180) 92.8% 
                                                                                                 P>0.05 
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TABLE 10 
Gender Distribution of IgG Seropositives 
Sex IgG seropositive donors 
(Total donors) 
Percent % 
Male  124(137) 90.51% 
Female 43(43) 100% 
Total 167(180) 92.8% 
                                                                                          P=0.036 
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TABLE 11 
 IgG seropositives on the basis of socioeconomic status 
Socioeconomic 
status 
IgG seropositive donors 
(Total donors) 
Percentage % 
High               19(23)           82.6% 
Middle             122(131)           93.12% 
Low               26(26)            100% 
Total             167(180)           92.8% 
                                                                                               P=0.041 
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           Demographic analysis showed, of the 180 donors, 137 (76.1%) 
were males and 43 (23.9%) were females. (Table 1; Fig 6) 
          Age distribution among the blood donors were 33.3% in 18-20 
years,     34.4% in 21-25 years, 18.9% in 26-30 years, 7.8% in 31-35 
years, 4.4% in 36-40 years, 1.1% in >40 years. (Table 2; Fig 7) 
          Percentage distribution of blood donors on the basis of occupation 
were 36% of Professionals, 42% of students, 13% of clericals, 9% of 
coolie. (Table 3; Fig 8)    
          Blood group distributions among the donors were 21.66% of ‘A’ 
positive, 30.55% of ‘B’ Positive, 35.6% of ‘O’ Positive, 6.1% of ‘AB’ 
positive. Rh D negative donors constitute about 6.1%. (Table 4; Fig 9) 
          Most of our donors belong to middle socioeconomic status 
(78.33%) followed by high (12.78%) and low (8.89%). (Table 5; Fig 10) 
          Among 180 voluntary blood donors, only one was found to be 
reactive for Hepatitis B Surface Antigen (HbsAg). (Table 6; Fig 11) 
 
 
 63
          CMV IgG antibody screening by ELISA showed that 13 were 
negative and 167 were positive, giving an overall CMV prevalence rate 
of 92.8%. None of the 180 blood donors were reactive for CMV IgM 
antibodies by ELISA test. (Table 7; Fig 12) 
          Of the 13 IgG seronegative blood samples, none were found to 
contain CMV DNA by real time PCR (RT-PCR). (Table 8; Fig 13) 
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DISCUSSION  
          The present study was undertaken to define the seroprevalence of 
CMV infection among voluntary blood donor population, since 
voluntary donors are expected to provide the major source of most blood 
transfusion requirements. Our blood centre has 100% voluntary blood 
donation, hence the present study comprised only of voluntary blood 
donors.   
           Kaur et al reported that voluntary donations need to be 
encouraged as voluntary donors are safer than replacement donors.91 
          As is evident from the results shown in our study, about 167 out 
of 180 (92.8%) donors were positive for IgG anti-CMV antibody, 
suggestive of past exposure to infection. (P=0.000; 95%CI 1.0340-
1.1104)  
IgG Seroprevalence of cytomegalovirus in various studies: 
STUDY PLACE IgG SEROPOSITIVITY 
Atul Kothari et al92 New Delhi 95% (n=200) 
Chaudhari et al93 Pune 87.9% (n=431) 
Mukundan et al94 Vellore 92% (n=212) 
Adjei et al95 Ghana 93% (n=264) 
Akinbami et al96 South Africa 96.7% (n=122) 
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STUDY PLACE IgG SEROPOSITIVITY 
Pultoo et al8 Mauritius 93.5% (n=584) 
Ahmed et al97 Malaysia 97.6% (n=172) 
Uslu et al98 Pakistan 85.4% (n=89) 
Amarapal et al99 Thailand 70.75% (n=441) 
Robert et al100 Missouri, USA 59% (n=223) 
Per Ljungman101 Netherlands 51.8% (n=23048) 
Seale et al102 Australia 57% (n=3593) 
 
From the above table, it is evident that our study results are in 
concordance with the results of developing countries. In contrast, the 
IgG seroprevalence is comparatively lower in developed countries.  
          On the other hand, none of the donors were positive for IgM anti-
CMV antibody, indicating the absence of primary infection. Our IgM 
anti CMV seropositivity was similar to the study done by Kothari et al92 
in New Delhi, Pal SR et al103 in Chandigarh, Adjei et al95 in Ghana.  
          In contrast, Akinbami et al reported 19.5% of the donors (n=122) 
to be positive for IgM anti-CMV antibody in South Africa.96 Amarapal 
et al99 reported 9.52% of Thai blood donors to be positive for IgM anti-
CMV antibody while Moniri et al10 reported 2.3% IgM seropositivity in 
Iran. These reflect donors with recent infection or reactivation. 
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          In our study, about 93.33% of the donors (56 out of 60) aged 
between 18-20 years were seropositive for CMV, as against 93.54% (58 
out of 62) in 21 to 25 years, 88.23% (30 out of 34) in 26 to 30 years, and 
92.85% (13 out of 14) in 31-35 years, and 100% in 36-40 years (8 out of 
8) and >40 years (2 out of 2). There was no statistically significant 
difference (P>0.05) in the CMV IgG status in different age groups. This 
differs with study done Smith et al who reported that the prevalence of 
the antibody to CMV increases with age. They reported that the 
prevalence of the antibody increased from 81% (in 21-30yrs) to 88% (in             
41-50yrs).77 Though there was 100% seropositivity above 36 years in 
our study, it may be likely due to smaller number of blood donors in that 
age group. So this may not be a significant finding with the relatively 
low sample size in that age group. 
          The IgG seropositivity among male donors in our study was 
90.51% (124 out of 137) while it is 100% (43 out of 43) in females. 
There was a significant statistical difference (P=0.036) in 
seroprevalence between sexes. This is similar to the study done by 
Pultoo et al who reported that the seropositivity was 93.1% in males and 
100% in females.8 Per Ljungman et al found that the risk of 
seropositivity increased with females (p<0.001).101  
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          About 82.6% (19 out of 23) of the donors in higher socio 
economic group are found to be seropositive for CMV while 93.12% 
(122 out of 131) in middle and 100% (26 out of 26) in lower socio 
economic group are found to be seropositive. There was a statistically 
significant difference (P=0.041) in IgG status in different socioeconomic 
status. This is in concordance with the study done by Pia et al in Finland 
who reported that the seropositivity increases in lower socio economic 
group when compared to higher socioeconomic group   (from 60.9% to 
76.4%; p=0.004).104 Sheevani et al in Punjab also reported that there was 
a decline in seropositivity with rising socioeconomic status.105 De Jong 
et al reported that infection with CMV is endemic in the developing 
countries and in areas of low socioeconomic conditions, which is 
predominantly related to the closeness of contacts within these 
populations.106 
          Since all the donors included in our study were voluntary blood 
donors, the prevalence of infections (HIV, HBV, HCV, Syphilis and 
Malaria) that are screened for mandatory tests in the study group were 
low. Only one among 180 blood donors was found to be positive for 
HbsAg. This donor was also positive for IgG anti-CMV antibody. 
Bayram et al reported that CMV is more common in chronic HBV and 
HCV patients. CMV infection was demonstrated in 52.3% of chronic 
HBV, and 36% of chronic HCV patients.107 
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         No correlation was observed between IgG seropositivity of CMV 
and either educational level, marital status or the blood groups. This is 
similar to the findings of Moniri et al10 and Kothari et al.92  
          To address the issue of window period, the 13 seronegative 
samples were subjected to RT-PCR for detecting CMV DNA. But none 
was found to contain CMV DNA. This is similar to the study done by 
Bitsch et al on 116 CMV seronegative donors, which showed absence of 
amplifiable DNA in all.78 Greenlee et al showed that CMV DNA was 
undetectable by real time PCR in both seronegative (n=93) and 
seropositive donors (n=110).108 
         However, our results differ from those of Larsson et al who found 
amplifiable CMV DNA in seronegative donors (19 of 140).109 But, the 
same authors in another study could not able to detect CMV DNA in a 
different study group of 20 seronegative donors.81 Nitsche et al found 5 
of 22 seronegative donors to have CMV DNA.110 The discrepancies 
might be explained by the use of different methods of extraction and 
DNA amplification. Roback JD et al had done the first multicentre trial 
to compare the sensitivity of PCR techniques and showed that some of 
the positive results in seronegative donors were due to spurious 
amplification of background genomic  DNA in the samples. They also 
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reported that at low viral concentrations in seropositive donors, not all 
aliquots of a given sample would contain sufficient target to be 
detectable by PCR, which may explain indiscriminate results in various 
studies.81 
          Ziemann et al reported that CMV DNA was detectable in 
peripheral blood for up to 269 days after the primary infection. 
Clearance of CMV DNA from blood correlated with clearance of IgM 
antibodies and the development of IgG antibodies.111 
          Due to high seropositivity (92.8%) in our study, discarding blood 
positive for IgG anti-CMV antibody is not feasible. The council of 
Europe has endorsed that alternatives like leukoreduced blood products 
can be used when seronegative blood is not available. However, CMV 
seronegative components should continue to be used in preference to 
leukoreduced components for the transfusion needs of patients who are 
at increased risk of CMV disease.20 
Future projects 
• To study the frequency of TT-CMV infection in seronegative 
patients when seropositive and seronegative blood components 
were transfused 
• To study the effect of leukofilters in TT-CMV transmission 
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SUMMARY AND CONCLUSION 
• The seroprevalence of IgG anti-CMV antibody among voluntary 
blood donors in Chennai is 92.8% (167 out of 180).  The high 
prevalence indicates the endemicity of infection, and this perhaps 
is related to socio-economic and environmental factor.  
• None of the IgG CMV seronegative donors were found to contain          
CMV DNA by RT-PCR. However, in order to rule out CMV 
infected donors in window period, it is imperative to confirm all 
cases of seronegative donors by RT-PCR. 
• IgG seropositivity is found to be significantly high in lower 
socioeconomic status and female population. 
• Age, educational qualification, marital status and blood group do 
not have any correlation with IgG CMV seropositivity.  
• None of the donors were found to be IgM anti-CMV antibody 
positive. Considering the cost being high and IgM antibody 
positive donors seldom found, screening for IgM anti-CMV 
antibody may be practiced only for high risk recipients.  
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• Seronegative blood component is utmost essential for high risk 
patients. However, if seronegative components are not available, 
IgG anti-CMV seropositive leukoreduced components may be 
used.  
• Due to dearth of seronegative donors in developing countries like 
India, latest techniques like pathogen inactivation may be made 
practically available in few centers catering high risk groups. 
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LIMITATIONS 
• Follow up of the seronegative donors could have been done to 
look for any seroconversion 
• Larger number of samples could have been studied 
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 No NAME
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ID AGE SEX
BLOOD 
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MARITAL 
STATUS OCCUPATION EDUCATION
SOCIO
ECONOMIC 
STATUS
TTI 
STATUS
IgM 
Anti-CMV
IgG 
Anti-CMV PCR
1 Danesh kanth 2844 18 M A1+ single student Graduate middle class NEG Neg Positive
2 rukmangathan 2848 20 M B+ single student Graduate middle class NEG Neg Positive
3 G Arun 2850 19 M O+ single student Graduate middle class NEG Neg Positive
4 Rajesh 2853 22 M B+ single Professional Graduate middle class NEG Neg Positive
5 pragadeeswari 2845 21 F A1+ single student Graduate middle class NEG Neg Positive
6 Thangarajan 2854 32 M B+ Married Clerical Post Graduate middle class NEG Neg Positive
7 Manikandan 2846 22 M A1B+ single student Graduate middle class NEG Neg Positive
8 saranraj 2849 20 M O+ single coolie illiterate low class NEG Neg Positive
9 Malarvizhi 2860 33 F O+ Married Clerical higher secondary middle class NEG Neg Positive
10 Sethubadmanaban 2856 19 M B+ single student Graduate middle class NEG Neg negative negative
11 Mahendra Prabu 2859 19 M O Neg single coolie illiterate low class NEG Neg Positive
12 Balu 2843 28 M O+ Married Clerical Graduate middle class NEG Neg Positive
13 Sujitha 2861 22 F A1+ single Professional Graduate middle class NEG Neg Positive
14 Selvaraj 2847 33 M O+ Married coolie illiterate low class NEG Neg Positive
15 Balaji 2858 22 M O+ single student Graduate middle class NEG Neg Positive
16 vasantha 2852 29 F B+ Married Professional Post Graduate middle class NEG Neg Positive
17 Ramanan 2857 38 M A1+ Married Clerical Graduate middle class NEG Neg Positive
18 Naveena 2851 19 F O+ single student Graduate middle class NEG Neg Positive
19 Sidharth 2842 19 M A1+ single student Graduate middle class NEG Neg Positive
20 Sathish Kumar 2855 19 M O+ single student Graduate middle class NEG Neg Positive
21 LakshmiNarayanakumar 2863 38 M O+ Married Clerical Graduate middle class NEG Neg Positive
22 Saravanakumar 2862 22 M A1+ single Clerical Graduate middle class NEG Neg Positive
23 Abdulwaheed 2865 34 M O+ Married Professional Post Graduate high class NEG Neg Positive
24 sabari 2864 20 F O+ single student Graduate middle class NEG Neg Positive
25 Venkateswari 3453 22 F O+ single Professional Graduate middle class NEG Neg Positive
26 kumaresan 3452 27 M O+ Married Professional Post Graduate high class NEG Neg Positive
27 Balu 3437 27 M A1+ Married Clerical Graduate middle class NEG Neg Positive
28 Ramprathap 3449 25 M O+ single Professional Graduate middle class NEG Neg Positive
29 Mannarsamy 3450 24 M O+ single student Graduate middle class NEG Neg Positive
30 Nandhakumar 3438 25 M A1+ single Professional Graduate high class NEG Neg negative negative
31 Gopika 3454 22 F A1B+ single student Graduate middle class NEG Neg Positive
32 Palaniappan 3456 26 M B+ Married Clerical Graduate middle class NEG Neg Positive
Sl.
 No NAME
DONOR 
ID AGE SEX
BLOOD 
GROUP
MARITAL 
STATUS OCCUPATION EDUCATION
SOCIO
ECONOMIC 
STATUS
TTI 
STATUS
IgM 
Anti-CMV
IgG 
Anti-CMV PCR
33 Nandakumar 3457 25 M A1+ single Professional Graduate middle class NEG Neg Positive
34 Parthiban 3442 26 M B+ Married Professional Graduate middle class NEG Neg Positive
35 Balaji 3444 26 M O+ single Professional Graduate middle class NEG Neg Positive
36 Sundar 3448 25 M A Neg single Clerical Graduate middle class NEG Neg Positive
37 Ranjithkumar 3443 25 M O+ single Professional Graduate middle class NEG Neg Positive
38 Kalaivani 3445 26 F B+ Married Professional Graduate high class NEG Neg Positive
39 Govardhanan 3435 25 M O+ single Clerical Graduate middle class NEG Neg Positive
40 Nareshkumari 3459 19 F B+ single student Graduate middle class NEG Neg Positive
41 Dineshkumar 3446 24 M O+ single Professional Graduate middle class NEG Neg negative negative
42 Anandan 3441 26 M O+ Married Clerical Graduate middle class NEG Neg Positive
43 Paneerselvam 3447 26 M A1+ single coolie higher secondary low class NEG Neg Positive
44 Deepika 3436 25 F A1+ single Professional Graduate high class NEG Neg Positive
45 Paramasivan 3458 34 M A1+ Married coolie illiterate low class NEG Neg Positive
46 Gangadaran 3455 25 M O+ single Professional Graduate middle class NEG Neg Positive
47 Thangarathinam 3451 25 M A1+ single Clerical secondary low class NEG Neg Positive
48 Prabhu 3440 26 M O+ single Professional Graduate middle class NEG Neg Positive
49 Shanmathi 3439 26 F B Neg Married Professional Graduate high class NEG Neg Positive
50 Vivek 3153 18 M O+ single student Graduate middle class NEG Neg Positive
51 Prakash 3168 19 M O+ single student Graduate high class NEG Neg negative negative
52 Neela 3147 18 F A+ single student Graduate middle class NEG Neg Positive
53 rathinam 3167 20 F A+ single student Graduate middle class NEG Neg Positive
54 vinotha 3165 19 F A+ single student Graduate middle class NEG Neg Positive
55 Sivakumar 3152 19 M A Neg single student Graduate middle class NEG Neg Positive
56 Praveenkumar 3150 19 M A+ single coolie illiterate low class NEG Neg Positive
57 selvakumari 3159 20 F B+ single Professional Graduate middle class NEG Neg Positive
58 Alukmanharzeen 3166 21 M A+ single student Graduate middle class NEG Neg negative negative
59 Vinothkumar 3154 21 M A Neg single student Graduate middle class NEG Neg Positive
60 Salimalik 3145 19 M O+ single coolie illiterate low class NEG Neg Positive
61 Venkatesh 3155 20 M O+ single student Graduate middle class NEG Neg Positive
62 Kameshwaran 3148 19 M A+ single student Graduate middle class NEG Neg Positive
63 Veerabhathiran 3160 32 M A+ Married Clerical Graduate middle class NEG Neg Positive
64 Ratheesh 3149 23 F A+ single Professional Post Graduate high class NEG Neg Positive
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65 Anandan 3164 19 M A+ single student Graduate middle class NEG Neg Positive
66 Dwarka 3144 20 F B+ single student Graduate middle class NEG Neg Positive
67 Vinothkumar 3157 20 M B+ single student Graduate middle class NEG Neg Positive
68 Jeevanandan 3151 21 M O+ single coolie illiterate low class NEG Neg Positive
69 Parthiban 3158 19 M O+ single student Graduate middle class NEG Neg Positive
70 Jagan mohini 3146 18 F O Neg single student Graduate middle class HBsAg Neg Positive
71 Vimalraj 3156 19 M B+ single student Graduate middle class NEG Neg Positive
72 Saravanan 3169 18 M A+ single student Graduate middle class NEG Neg Positive
73 Giriprashanth 3170 18 M B+ single student Graduate middle class NEG Neg Positive
74 Rajkumari 2838 21 F O+ single student Graduate middle class NEG Neg Positive
75 Madheshwaran 2822 23 M A1+ single Professional Graduate high class NEG Neg Positive
76 Karthika 2823 23 F B+ single Professional Post Graduate high class NEG Neg Positive
77 Vijaykrishnan 2833 30 M B+ Married Clerical Graduate middle class NEG Neg Positive
78 Sathish Kumar 2825 26 M A+ single Professional Graduate middle class NEG Neg negative negative
79 LakshmiNarayanakumar 2821 26 F O+ Married Professional Graduate high class NEG Neg Positive
80 Bsikaisan 2828 20 M A+ single student Graduate middle class NEG Neg Positive
81 Sheiksirajudeen 2824 22 M O+ single student Graduate middle class NEG Neg Positive
82 Azhagarsamy 2834 29 M A+ Married Clerical Graduate middle class NEG Neg Positive
83 Purishothaman 2832 20 M B Neg single student Graduate middle class NEG Neg Positive
84 saravana Vidhya 2831 35 F A2+ Married coolie illiterate low class NEG Neg Positive
85 Rajesh 2835 22 M B+ single student Graduate middle class NEG Neg Positive
86 Sadhamhussain 2840 20 M O+ single student Graduate middle class NEG Neg Positive
87 Vajiravelu 2819 29 M B+ Married Professional Graduate high class NEG Neg Positive
88 Arunkumar 2841 27 M O+ Married Professional Graduate middle class NEG Neg negative negative
89 Meganathan 2827 21 M O+ single student Graduate middle class NEG Neg Positive
90 Devendran 2830 20 M AB+ single student Graduate middle class NEG Neg Positive
91 Kumari 2826 19 F B+ single student Graduate middle class NEG Neg Positive
92 Kavitha 2820 19 F O+ single student Graduate middle class NEG Neg Positive
93 Ashokkumar 2836 24 M O+ single Professional Graduate middle class NEG Neg Positive
94 Paulraj 2677 32 M AB+ Married coolie illiterate middle class NEG Neg Positive
95 Murthy 2698 40 M AB+ Married coolie illiterate low class NEG Neg Positive
96 Vaasantha 2693 22 F O+ single Professional Graduate middle class NEG Neg Positive
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97 Sundarajan 2676 36 M AB+ Married Clerical Graduate middle class NEG Neg Positive
98 Jeevanandham 2674 23 M B+ single Clerical secondary low class NEG Neg Positive
99 Gilbertraj 2678 36 M B+ Married Professional Graduate middle class NEG Neg Positive
100 Sundarapandiyan 2680 25 M A1+ single Professional Post Graduate middle class NEG Neg Positive
101 Anumathon 2683 25 F O+ single student Graduate middle class NEG Neg Positive
102 Kannusamy 2691 30 M O+ Married coolie illiterate low class NEG Neg Positive
103 Francis 2675 31 M O+ Married Professional Graduate middle class NEG Neg Positive
104 Rengaraja 2672 26 M B+ single Professional Graduate high class NEG Neg negative negative
105 Sathish Kumar 2742 23 M O+ single student Graduate middle class NEG Neg Positive
106 Karunanidhi 2733 42 M B+ Married Clerical Graduate middle class NEG Neg Positive
107 Narayani 2741 24 F O+ single Professional Graduate high class NEG Neg Positive
108 Nagraj 2711 25 M A+ single Clerical higher secondary low class NEG Neg Positive
109 sundaramurthy 2716 23 M B+ single Professional Graduate high class NEG Neg Positive
110 Pandian 2724 46 M O+ Married Clerical secondary middle class NEG Neg Positive
111 Silambarasan 2743 23 M B Neg single student Graduate middle class NEG Neg Positive
112 Saravanan 2723 21 M B+ single student Graduate middle class NEG Neg Positive
113 Jegadeeswari 2703 25 F AB+ single Professional Graduate high class NEG Neg Positive
114 Sathish  2715 25 M B+ single coolie illiterate low class NEG Neg Positive
115 sathiyasundaram 2705 22 M O+ single student Graduate middle class NEG Neg Positive
116 Madhusudhanan 3363 18 M A+ single student Graduate middle class NEG Neg Positive
117 Senthilnathan 3369 21 M A+ single student Graduate middle class NEG Neg negative negative
118 Vigneshwari 3361 19 F A Neg single student Graduate middle class NEG Neg Positive
119 Sathish 3362 18 M A+ single student Graduate middle class NEG Neg Positive
120 Raguram gayathri 3379 20 F O+ single coolie illiterate low class NEG Neg Positive
121 Ganapathy 3374 19 M O+ single student Graduate middle class NEG Neg Positive
122 Mohammadarif 3383 19 M B+ single student Graduate middle class NEG Neg Positive
123 Kumaran 3386 18 M O+ single student Graduate middle class NEG Neg Positive
124 Abdulajees 3366 19 F O+ single coolie illiterate low class NEG Neg Positive
125 Raghupathy 3359 19 M A1+ single student Graduate middle class NEG Neg negative negative
126 ManoJequson 3364 20 M A+ single student Graduate middle class NEG Neg Positive
127 Praveena 3360 19 F B+ single student Graduate middle class NEG Neg Positive
128 Anburaj 3373 19 M O+ single student Graduate middle class NEG Neg Positive
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129 Ramalingam 3372 18 M A+ single student Graduate middle class NEG Neg Positive
130 Prabakaran 3381 19 M B+ single student Graduate middle class NEG Neg Positive
131 Surajeef 3389 18 F B+ single student Graduate middle class NEG Neg Positive
132 Sourabh 3377 18 M B+ single student Graduate middle class NEG Neg Positive
133 Sarathkumar 3375 20 M O+ single student Graduate middle class NEG Neg Positive
134 Manojkumar 3365 18 M B+ single student Graduate middle class NEG Neg Positive
135 Venkatesh 3378 20 M B+ single coolie primary low class NEG Neg Positive
136 Akhil 3368 19 F A+ single student Graduate middle class NEG Neg Positive
137 Sakthinathan 3367 19 M O+ single student Graduate middle class NEG Neg Positive
138 Mohankumar 3376 19 M B+ single student Graduate middle class NEG Neg Positive
139 Kevin 3370 18 M AB+ single student Graduate middle class NEG Neg Positive
140 Praveenkumar 3358 18 M O+ single student Graduate middle class NEG Neg Positive
141 Vidhya 2974 25 F O+ Married Clerical primary low class NEG Neg Positive
142 Jacob Antony 2975 27 M O+ Married Professional Graduate middle class NEG Neg negative negative
143 Manikandan 2986 32 M B+ Married coolie high school low class NEG Neg Positive
144 Banupradeep 2999 24 M O Neg single Professional Graduate high class NEG Neg Positive
145 Radhika 2988 24 F O+ single Professional Graduate middle class NEG Neg Positive
146 Pandian 2980 40 M A1+ Married Professional Graduate high class NEG Neg Positive
147 Ashokkumar 2993 26 M O+ single Professional Graduate middle class NEG Neg Positive
148 Karthika 2991 28 F A1+ Married Professional Graduate middle class NEG Neg Positive
149 Shanmuganathan 2997 19 M B+ single student Graduate middle class NEG Neg negative negative
150 Miteshvarma 2990 25 M A1+ single Professional Graduate high class NEG Neg Positive
151 Anand 2979 34 M A1+ Married Professional Post Graduate middle class NEG Neg Positive
152 Altongo 2983 26 M O+ single coolie primary low class NEG Neg Positive
153 Thriveni 2996 23 F A1+ single Professional Graduate middle class NEG Neg Positive
154 Ramasundarajan 3006 25 M B+ single Professional Graduate middle class NEG Neg Positive
155 Venka 3014 24 F A1+ single Clerical primary low class NEG Neg Positive
156 Aravindan 3018 28 M AB+ Married Professional Graduate middle class NEG Neg Positive
157 Kirubashankar 3017 26 M O Neg single Professional Graduate high class NEG Neg Positive
158 Balu 3015 28 M B+ single Clerical higher secondary middle class NEG Neg Positive
159 Naveen 3011 23 M A1+ single student Graduate middle class NEG Neg Positive
160 Arajitsarkar 3008 28 M B+ Married Professional Graduate high class NEG Neg Positive
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161 Madhanmohan 3004 33 M B+ Married Clerical higher secondary middle class NEG Neg Positive
162 Srivudhya 3012 24 F B+ single Professional Graduate high class NEG Neg Positive
163 Dhilipraj 3002 23 M A1+ single student Graduate middle class NEG Neg Positive
164 Chandrasekaran 3013 24 M B+ single Professional Graduate middle class NEG Neg Positive
165 Kadharmoideen 3010 21 M B+ single student Graduate middle class NEG Neg Positive
166 Boopalan 3016 25 M O+ single Professional Graduate middle class NEG Neg Positive
167 Sriram 799 39 M A+ Married coolie illiterate low class NEG Neg Positive
168 Krishnakumari 801 35 F O+ Married Professional Graduate middle class NEG Neg Positive
169 Muthukumaran 803 23 M A1B+ single Professional Post Graduate middle class NEG Neg Positive
170 Zaheer Mohammad 822 30 M O+ Married Clerical Graduate middle class NEG Neg Positive
171 Praveen kumar 817 29 M A1+ Married coolie illiterate low class NEG Neg Positive
172 Rajamanickam 813 27 M A1+ single Professional Graduate middle class NEG Neg positive
173 Subhashini 811 27 F O+ Married Professional Graduate middle class NEG Neg Positive
174 Jafarali 807 23 M B+ single student Graduate middle class NEG Neg Positive
175 Sivakumar 805 28 M A1+ single coolie illiterate low class NEG Neg Positive
176 Vikramkumar 819 24 M B+ single Professional Graduate middle class NEG Neg Positive
177 Karthik 815 29 M A2B+ Married Professional Graduate middle class NEG Neg Positive
178 Sakthivel 827 32 M O+ Married Professional Post Graduate high class NEG Neg negative negative
179 Sivakumar 823 36 M O+ Married Professional Graduate middle class NEG Neg Positive
180 Raghuram 825 29 M B+ Married Clerical Graduate middle class NEG Neg Positive
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS 
 
            AABB         -         American Association of Blood Banks 
          BMT            -         Bone Marrow Transplantation 
 CMV    - Cytomegalovirus 
          ELISA         -         Enzyme Linked Immunosorbent Assay 
          FFP              -         Fresh Frozen Plasma 
 HbsAg - Hepatitis `B’ surface antigen 
          HBV            -         Hepatitis B Virus 
 HCV  - Hepatitis `C’ Virus 
 HHV       - Human herpes virus  
 HIV     - Human Immunodeficiency Viruses 
 HTLV - Human T-cell lymphotropic Virus 
          IFN  -         Interferon 
          IL-6  - Interleukin- 6 
 NAT  - Nucleic acid Amplification Testing 
 PBMNC -  Peripheral Blood Mononuclear Cells 
 RT-PCR - Real Time Polymerase Chain Reaction 
 TNF  -  Tumour Necrosis Factor 
 TT-CMV - Transfusion Transmitted Cytomegalovirus 
 TTI  - Transfusion Transmitted Infections    
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Fig 1. CMV infected cell showing cytomegalia with nuclear and 
cytoplasmic inclusions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. CMV IgG ELISA Kit 
 
 
 
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. CMV IgM ELISA Kit 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. IgG anti-CMV ELISA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6. IgM anti-CMV ELISA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7. ROCHE Light Cycler 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
